Navigation Links
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results
Date:2/11/2009

December 31, December 31, 2008 2007 Cash flows from operating activities: Net loss $(51,064,241) $(74,069,690) Adjustments to reconcile net income to net cash used in operating activities: Depreciation and amortization 530,805 571,586 Stock-based compensation 13,387,789 19,622,814 Loss on disposal of assets (173) 28,713 Accretion of discount on investments (235,163) (1,571,905) Changes in assets and liabilities: Prepaid expenses and other current assets 495,200 168,987 Deposits 150,000 - Accounts payable (2,475,697) 204,029 Accrued expenses (6,892,577) 3,465,028 Deferred grant revenue - (147,464) Other liabilities 148,728 86,644 Net cash used in operating activities (45,955,329) (51,641,258) Cash flows from investing activities: Purchases of property and equipment (943,659) (279,433) Proceeds from sales of property and equipment - 200,179 Purchases of marketable securities (14,786,080) (138,953,879) Proceeds from sales of marketable securities 11,258,094 3,577,859 Maturities of marketable securities 47,560,000 86,695,000 Net cash provided by (used in) investing activities 43,088,355 (48,760,274) Cash flows from financing activities: Proceeds from exercise of stock options and warrants
'/>"/>
SOURCE Vanda Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
2. Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
3. Vanda Pharmaceuticals to Announce Second Quarter 2008 Financial Results on August 5, 2008
4. LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests
5. Vanda Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
6. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Roth Capital Partners 21st Annual OC Growth Stock Conference
8. Sagent Pharmaceuticals Announces Expansion of Cefazolin Product Line to Include Cefazolin for Injection, USP in 500mg Single-Dose Vial
9. PacificGMP and LigoCyte Pharmaceuticals Announce cGMP Manufacturing Collaboration
10. Diffusion Pharmaceuticals Announces Completion of a $2.9 Million Private Placement and Company Presentations at Upcoming Industry Conferences in Geneva, Switzerland and Naples, Florida
11. Tigris Pharmaceuticals Files IND Application for GGTI-2418
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... May 17, 2013 Tooth decay is an ... active signs of the disease. The World Health Organization says ... 100% of adults have cavities. What are the long-term effects ... showing a strong connection between the oral bacterial imbalance and ... disease so rampant, yet it is also 100% preventable? Answer: ...
(Date:5/16/2013)... Zealand (PRWEB) May 16, 2013 In late ... invited to speak to doctors in China about Appearance ... and NZ, this was her first trip to lecture in ... Hart visited Guangzhou and Fuzhou, home to 12 and 7 ... China is very high at this point in time. As ...
(Date:5/16/2013)... Ore. , May 16, 2013  HealthSparq, ... many of the nation,s largest regional health plans, ... America,s Health Insurance Plans (AHIP) Institute 2013 conference ... highlight survey results showing how health insurance companies ... for the consumer and marketplace demands for increased ...
(Date:5/16/2013)... May 16, 2013 On average, developing ... over one billion dollars. Despite this investment, less than ... this high, is your clinical trial design optimally structured ... best outcomes? , Dr. Frederic Sax, Global Head of ... the use of data, information and technology in upfront ...
Breaking Biology Technology:Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 3HealthSparq to Reveal New Healthcare Transparency Benchmark Study at AHIP Institute 2013 2HealthSparq to Reveal New Healthcare Transparency Benchmark Study at AHIP Institute 2013 3Optimizing Clinical Trials Outcomes through Computer Assisted Design, New Life Science Webinar Hosted by Xtalks 2
... 2008 NFPA 1584 establishes the routine use of Pulse CO-Oximetry as a ... the dangers of CO ... Poisoning, ... and Measure-Through Motion and Low,Perfusion pulse oximetry, announced today that the National ...
... Endpoint for Phase 3 Registration Trial No Later Than ... ... Inc. (Nasdaq:,FVRL), a biopharmaceutical company developing patient-specific, active,immunotherapies for the treatment of ... 2007. For the quarter and year,ended December 31, 2007, the Company reported ...
... U.S. Department of Energy,s Ames ,Laboratory have come ... and distribute ,the massive amounts of data that ... the world. The new technology, a three-dimensional photonic ... multiple ,wavelength channels (wavelengths of light) traveling along ...
Cached Biology Technology:National Fire Protection Association (NFPA) Sets New National Standard for CO Screening by Pulse CO-Oximetry(TM) 2National Fire Protection Association (NFPA) Sets New National Standard for CO Screening by Pulse CO-Oximetry(TM) 3National Fire Protection Association (NFPA) Sets New National Standard for CO Screening by Pulse CO-Oximetry(TM) 4Favrille Reports Fourth Quarter and Year End 2007 Financial Results 2Favrille Reports Fourth Quarter and Year End 2007 Financial Results 3Favrille Reports Fourth Quarter and Year End 2007 Financial Results 4Favrille Reports Fourth Quarter and Year End 2007 Financial Results 5Favrille Reports Fourth Quarter and Year End 2007 Financial Results 6Favrille Reports Fourth Quarter and Year End 2007 Financial Results 7Favrille Reports Fourth Quarter and Year End 2007 Financial Results 8Favrille Reports Fourth Quarter and Year End 2007 Financial Results 9New filter clears up fiber optic communications 2New filter clears up fiber optic communications 3
(Date:5/16/2013)... SPARTANBURG, S.C. , May 16, 2013 /PRNewswire/ ... film in combination with a custom thin film ...  the highest forensic quality roll image in the ... market today. Sherlock, an Appendix F Mobile ID ... provides a 95% reduction in size and weight ...
(Date:5/16/2013)... the bone marrow in the liver, the spleen ... show that a specific type of immune cell facilitates ... hematopoiesis is essential for the function of the immune ... the liver and the spleen. Later the process is ... serves as the sole source of blood cells for ...
(Date:5/16/2013)... conservationist working in Cameroon and the manager of San ... awarded the prestigious Whitley award. The Whitley award ... Green Oscars" because it celebrates the extraordinary achievements of ... countries. Abwe was selected for the award due ... Ebo Forest and its wildlife inhabitants., HRH The Princess ...
Breaking Biology News(10 mins):Herpes infections: Natural killer cells activate hematopoiesis 2Cameroon researcher wins prestigious 'Green Oscar' 2Cameroon researcher wins prestigious 'Green Oscar' 3
... 2008 American Society for Microbiology (ASM) sanofi-aventis U.S. ... Director, WWAMI Regional Center of Excellence for Biodefense ... by an unrestricted grant from sanofi-aventis U.S., this ... Through his professional life, Dr. Stamm has worked ...
... (Washington, D.C. July 14, 2008) EPA has released ... Criteria." This is EPA,s latest evaluation of the ... resulting from exposures to oxides of nitrogen, particularly nitrogen ... data, particularly epidemiological studies, since the last scientific review ...
... 2008 The outlook for air quality in Beijing during ... government can do to improve it. That,s the ... who analyzed pollution data collected regularly for the last five ... component and a regional component to the pollutants that cause ...
Cached Biology News:URI researcher: China can't fully fix air quality problem for Olympics 2
... allows the Thermo-Fast® 96 ... PCR plates to be ... PRISM® 3700 capillary sequencer. ... information on the software ...
Spectrolyse (pL) PAI kit is a two-stage indirect enzymatic assay for the quantitative determination of Plasminogen Activator Inhibitor (PAI-1) activity in plasma. Sample Type: plasma...
Rabbit anti-CRSP1 (TRAP220), Polyclonal Antibody, Unconjugated Applications: Immunohistochemistry - 1:100 - 1:500...
... White lyophilized solid. PROTECT FROM LIGHT. PACKAGED ... of γ-secretase. Equipotently inhibits the release of ... 2.6 μM) and Aβ x-42 (ED ... cells stably transfected with the Amyloid Precursor ...
Biology Products: